> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # The Scheduling Problem Holding Back Cell and Gene Therapy - URL: https://nexi.fund/glidepath-health-cgt-logistics-2026/ - Published: 2026-09-20T14:00:54.000Z - Updated: 2026-09-20T14:00:54.000Z - Description: Glidepath Health launched with backing from AlleyCorp and A-Squared Ventures and an exclusive license to Memorial Sloan Kettering's ImmunoChain technology. The company is betting that the operational logistics of cell and gene therapy, not the biology, now limit who gets treated. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-4, #hook-number, #track-E $10.7 billion is what the world already spends each year moving living cells between patients, laboratories and back again. Glidepath Health, which exited stealth on September 15, is betting that this plumbing, not the science, is what holds cell and gene therapy back. The New York company launched an AI-driven platform that coordinates the operational chain behind these treatments: apheresis collection, manufacturing slots, and chain of identity and custody from collection through infusion. Its core technology is licensed exclusively from Memorial Sloan Kettering Cancer Center, where the system, called ImmunoChain, was built. The startup is backed by AlleyCorp and A-Squared Ventures, with AlleyCorp principal Omar Njie and A-Squared managing partner Nadav Shimoni on the board. Financial terms were not disclosed. Initial deployments at treatment centers are planned for this year. ## The bottleneck is scheduling, not science Ask an oncology nurse what delays a CAR T-cell infusion and the answer is rarely biology. A patient's access to the therapy can hinge on whether one coordinator succeeded in lining up an apheresis slot and a manufacturing slot in the same week, tracked across a dozen inboxes. That gap is where the treatment quietly stalls. The mismatch carries a hard cost. A single CAR T-cell course is among the most expensive treatments in oncology, and a manufacturing slot that sits idle while a collection date slips is capital that never returns. Vein-to-vein time, the interval between drawing a patient's cells and returning the finished product, is the field's real throughput measure. It is governed by calendars, not assays. > That is not a science problem. It is an infrastructure problem, and it is solvable.— Andy Moye, PhD, Chief Executive Officer and Co-Founder, Glidepath Health The infrastructure case has a financial surface. Cell and gene therapy third-party logistics was a $10.71 billion market in 2024 and is projected to reach $20.04 billion by 2030, an 11.05% compound annual rate, according to Research and Markets. Orchestration software sits on top of that spend, where a platform of record can charge for visibility instead of for trucks and dry ice. $20.04B CGT logistics, 2030 #### Cell and gene therapy third-party logistics market Up from $10.71 billion in 2024 — an 11.05% compound annual rate. *Research and Markets, 2026* 🎯 Glidepath is selling coordination, not biology, and coordination is where the current capacity losses sit. The exclusive MSK license gives it a defensible starting position in a fragmented field. The bet only pays if manufacturers accept one shared platform of record. ## Why biology still gets the last word The infrastructure thesis has a weak flank. It assumes the therapies are good enough that logistics is the marginal constraint. That assumption is doing a great deal of work. Cell and gene therapy carries a long memory of efficacy that did not survive scale. A construct that shrinks tumors across forty patients can behave differently in a cohort ten times larger. Durability, not delivery, is what regulators and payers ultimately underwrite, and no scheduling layer can manufacture a durable response. The supply side is just as stubborn. Capacity, especially for viral vectors, is the constraint the industry cites most often — a question of bioreactors and skilled staff, not of calendar coordination. A platform that synchronizes apheresis and manufacturing still cannot conjure an AAV batch that does not exist. Reimbursement is the quieter constraint. Cell and gene therapies are frequently one-time treatments priced at levels most payers will only cover with conditions, and they have answered with outcomes-based contracts, installment payments and narrow eligibility rules. A perfectly coordinated supply chain still has to clear that gate. Restrict a therapy to patients who have failed two prior lines of treatment, and the eligible population shrinks before logistics ever becomes the bottleneck. Cost compounds the point. When a therapy is priced at the high end of oncology and indicated for a narrow population, the binding constraint is often reimbursement, not scheduling. As we [wrote in September](https://nexi.fund/hexembio-stem-cell-rejuvenation-2026), capital keeps flowing toward the cell-level science itself, with HexemBio's $15.5 million stem-cell bet landing the same week. Investors still treat the biology as the value-creating layer and the logistics as a service layer beneath it. ## The data layer is the real prize Strip away the scheduling pitch and Glidepath is selling a position: the system of record for advanced therapies. Every apheresis appointment, every manufacturing slot, every chain-of-custody handoff generates a record. Whoever owns that record owns the operational truth of a therapy program. That is a different business from freight. A logistics provider moves cells and bills per shipment. A platform of record sits between the treatment center, the sponsor and the manufacturer, and accumulates the data that tells each party what happens next. The company says it already maintains chain of identity and chain of custody from collection through infusion, integrated with hospital records rather than bolted alongside them. The economics of that position compound. A single CAR T-cell journey can involve a hospital, a collection center, a contract manufacturer, a courier and a payer, each running its own system. Standardizing those handoffs creates switching costs that a pure courier never earns. It also hands the platform the metrics its buyers care about: vein-to-vein time, slot utilization and, eventually, which patients actually reach infusion. The moat is not the license alone. Memorial Sloan Kettering's ImmunoChain gives Glidepath a defensible starting technology and a marquee reference customer, but exclusive academic licenses are time-limited by their terms and replicable by a determined competitor. The installed base is harder to copy. If Glidepath becomes the default screen in enough treatment centers, a sponsor that wants visibility into its own therapy has to join rather than build. ## What the numbers actually say | Market | Base | Outlook | | ----------------------------- | -------------- | ----------------------------- | | **Third-party CGT logistics** | $10.71B (2024) | $20.04B by 2030 — 11.05% CAGR | | **CGT therapies, overall** | $10.44B (2026) | $47.18B by 2035 | Research and Markets; Towards Healthcare, 2026 Read together, the two rows frame the debate. The therapies are forecast to compound far faster than the logistics layer that supports them. Glidepath is positioning itself as the system of record for that narrower layer, which means its ceiling depends less on how many cells move than on how many manufacturers agree to route every movement through one screen. That is a software company's economics attached to a clinical supply chain. It is also why the company's own framing leans on visibility and data rather than on physical capacity: the platform promises pharma sponsors access to operational and clinical data, and treatment centers a single view from referral to infusion. ## What to watch 📊 **Signals that decide the thesis** Whether Glidepath's 2026 treatment-center deployments advance from pilot to live patient journeys Whether pharma sponsors standardize on one orchestration platform or keep parallel vendor stacks Whether the MSK license generates further academic spin-ins on the same supply-chain model Whether the next reimbursement decision rewards operational outcomes rather than only clinical ones Glidepath's first real test is not technical. It is whether the pharma sponsors who own the patient relationship will tolerate a single intermediary between their therapy and the treatment center. If they will, the logistics layer becomes infrastructure. If they will not, it stays a scheduling tool with a licensing story attached. The science of cell and gene therapy will keep advancing either way. The question Glidepath raises is narrower and more interesting: how much of the next decade's value sits in making the therapy, and how much sits in getting it to the patient on time. [ Glidepath Health exits stealth with a cell therapy logistics platform Primary release: platform launch, exclusive MSK ImmunoChain license, and investor structure. Business Wire ](https://www.businesswire.com/news/home/20260915430311/en/Glidepath-Health-Launches-to-Bring-Operational-Certainty-to-Cell-and-Gene-Therapy-Delivery?ref=nexi.fund) Primary source for the event: platform details, license, and board composition. [ Cell and gene therapy third-party logistics: $10.7B to $20B Market sizing for third-party CGT logistics and the outlook to 2030. Research and Markets ](https://www.researchandmarkets.com/reports/6085876/cell-gene-therapy-third-party-logistics-market?ref=nexi.fund) Industry estimate that frames the service layer Glidepath is entering. [ Cencora: cell and gene therapy logistics A major distributor offering its own CGT logistics — a baseline for comparison. Cencora ](https://www.cencora.com/solutions/cgt-logistics?ref=nexi.fund) An incumbent CGT logistics player against which Glidepath's position is assessed.